Ovarian Cancer Coverage from Every Angle
Advertisement
Advertisement

Ongoing CE Activities

Advances in™ PARP Inhibitors: Expanding the Application of Novel Agents in Ovarian Cancer
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care-Ovarian Cancer
Cancer Summaries and Commentaries™: Recent Advances in the Treatment of Gynecological Cancers: What we Learned in Barcelona
Current and Future Directions in PARP Inhibition
Addressing Current Questions and Emerging Considerations with the Use of PARP Inhibitors in the Management of Ovarian Cancer
Exploring the Evolving Role of PARP Inhibition and Immunotherapy in Gynecological Cancers
Genetic Familial High-Risk Assessment Breast Ovarian And Pancreatic Version 1.2020
Investigator Perspectives on the Current and Future Management of Newly Diagnosed Ovarian Cancer
Community Practice Connections™: Managing Postoperative Pain: The Clinical Impact of Opioid-Sparing Strategies on Patients With Breast Cancer
Modest Responses With Immunotherapy Combo for Advanced Ovarian Cancer
NCCN Guidelines® Insights - Ovarian Cancer, Version 1.2019
GOG 0218: No Overall Survival Boost With Bevacizumab in Ovarian Cancer
Novel Agents and Emerging Strategies in the Management of Gynecologic Cancers
Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A Complimentary CNE (NCPD) Live Webinar Series
Ovarian Cancer: Therapeutic Updates, Best Practices, and Emerging Treatments
Ovarian Cancer Tumor Board: Leveraging Evolving Data Sets on PARP Inhibitors in Ovarian Cancer to Inform Treatment Decision-Making
Risk Stratification for Breast and Ovarian Cancer
Second Surgery in Recurrent Ovarian Cancer Did Not Lead to Survival Benefit
Selection of Optimal First-Line and Maintenance therapy in Advanced Ovarian Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.